MedPath

Korea Otsuka Pharmaceutical Co., Ltd.

๐Ÿ‡ฐ๐Ÿ‡ทSouth Korea
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka.co.kr

Pletaal SR Post Marketing Observational Study

Completed
Conditions
Ischemic Symptoms
Cerebral Infarction
First Posted Date
2013-02-04
Last Posted Date
2019-03-01
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
3635
Registration Number
NCT01782833
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Kyungpook National University Hospital, Daegu, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

NHIC Ilsan Hospital, Goyang, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Inje University Seoul Pail Hospital, Seoul, Korea, Republic of

and more 1 locations

Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy

Phase 2
Completed
Conditions
Diabetic Nephropathy
Interventions
First Posted Date
2012-11-15
Last Posted Date
2017-05-03
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
126
Registration Number
NCT01726816
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

The Catholic university of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Kyungpook National University, DaeGu, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Yeungnam University Medical Center, DaeGu, Korea, Republic of

and more 13 locations

A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease

Phase 4
Completed
Conditions
Chronic Occlusive Arterial Disease
Interventions
Drug: Pletaal SR capsule
First Posted Date
2012-10-22
Last Posted Date
2022-06-10
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
101
Registration Number
NCT01711333
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

KYUNG-HEE UNIVERSITY HOSPITAL at GANGDONG, Seoul, Korea, Republic of

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

Phase 4
Terminated
Conditions
Hyponatremia and Extracellular Fluid in Cirrhotic
Interventions
Drug: Placebo
First Posted Date
2012-03-13
Last Posted Date
2022-03-04
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
74
Registration Number
NCT01552590
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Hallym Univ. Chuncheon Sacred Heart Hospital, Bucheon, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Soonchunhyang Univ. Bucheon Hospital, Bucheon, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Wonju Christian Hospital, Wonju, Korea, Republic of

Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina

Phase 2
Completed
Conditions
Variant Angina
Interventions
Drug: Placebo
First Posted Date
2011-10-03
Last Posted Date
2012-07-16
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
50
Registration Number
NCT01444885
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

ChungNam Univ. Hospital, DaeJeon, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Gangneung Asan Hospital, Gangneung, Korea, Republic of

and more 7 locations

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2010-09-09
Last Posted Date
2022-06-10
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
110
Registration Number
NCT01197066

Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety

Phase 2
Completed
Conditions
Peripheral Artery Disease
Interventions
First Posted Date
2010-06-11
Last Posted Date
2022-07-18
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
80
Registration Number
NCT01142284
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Asan Medical Center, Seoul, Korea, Republic of

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2009-11-17
Last Posted Date
2010-03-11
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
46
Registration Number
NCT01014416
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Seoul National University Hospital, Seoul, Korea, Republic of

Pharmacokinetics Study for Probucol

Phase 4
Completed
Conditions
Healthy
Interventions
First Posted Date
2009-10-23
Last Posted Date
2022-03-04
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
30
Registration Number
NCT01000467
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Seoul national univeristy, Seoul, Korea, Republic of

A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo of CDP870
Drug: CDP870 200mg
First Posted Date
2009-10-12
Last Posted Date
2012-09-27
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
127
Registration Number
NCT00993317
Locations
๐Ÿ‡ฐ๐Ÿ‡ท

Kyungpook National University Hospital, Daegu, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Catholic University Hospital of Daegu, Daegu, Korea, Republic of

๐Ÿ‡ฐ๐Ÿ‡ท

Eulji University Hospital, Daejeon, Korea, Republic of

and more 12 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath